ACHIEVE PROGRAMMABLE AUOMATED BIOPSY SYSTEMS
Device Facts
| Record ID | K141552 |
|---|---|
| Device Name | ACHIEVE PROGRAMMABLE AUOMATED BIOPSY SYSTEMS |
| Applicant | Care Fusion |
| Product Code | KNW · Gastroenterology, Urology |
| Decision Date | Sep 5, 2014 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 876.1075 |
| Device Class | Class 2 |
Indications for Use
The Achieve Programmable Automatic Biopsy System is intended for use in obtaining core biopsy samples from soft tissue such as kidney, liver, prostrate, spleen, lymph nodes, and various soft tissue masses. Not intended for use in bone. The Achieve Programmable Automatic Biopsy System is also indicated to provide breast tissue samples for diagnostic sampling of breast abnormalities. It is designed to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality. The extent of histologic abnormality cannot be reliably determined from its mammographic appearance. Therefore, the extent of removal of the imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality (e.g., malignancy). When the sampled abnormality is not histologically benign, it is essue margins be examined for completeness of removal using standard surgical procedures.
Device Story
Achieve Programmable Automatic Biopsy System is a spring-loaded, automatic biopsy instrument used to obtain core tissue samples for histologic examination. Device features automatic and delay firing modes for penetration of dense, calcified, or fibrous tissue. Operated by clinicians in clinical settings; device provides precise control for sampling soft tissue organs and masses. Output is a physical tissue specimen retrieved via needle; healthcare providers use this specimen for microscopic evaluation to diagnose abnormalities. System benefits patients by enabling minimally invasive, accurate tissue acquisition for diagnostic purposes.
Clinical Evidence
No clinical data. Substantial equivalence determined via bench testing only, including biocompatibility, sterilization residuals, weld strength, firing speed, and ultrasound visibility comparisons against predicate devices.
Technological Characteristics
Spring-loaded automatic biopsy system. Materials include stainless steel (ASTM F899-95, BS EN ISO 9626:1995). Features automatic and delay firing modes. Sterilized via Ethylene Oxide (ISO 11135:2007). Packaging compliant with ANSI/AAMI/ISO 11607:2006. No software or electronic components.
Indications for Use
Indicated for obtaining core biopsy samples from soft tissue (kidney, liver, prostate, spleen, lymph nodes, soft tissue masses) and diagnostic sampling of breast abnormalities. Not for use in bone.
Regulatory Classification
Identification
A gastroenterology-urology biopsy instrument is a device used to remove, by cutting or aspiration, a specimen of tissue for microscopic examination. This generic type of device includes the biopsy punch, gastrointestinal mechanical biopsy instrument, suction biopsy instrument, gastro-urology biopsy needle and needle set, and nonelectric biopsy forceps. This section does not apply to biopsy instruments that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.
Predicate Devices
Submission Summary (Full Text)
{0}------------------------------------------------
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 5, 2014
CareFusion Ms. Joy Greidanus Regulatory Affairs Manager 75 North Fairway Drive Vernon Hills, IL 60061
Re: K141552
Trade/Device Name: Achieve Programmable Automatic Biopsy Systems Regulation Number: 21 CFR 876.1075 Regulation Name: Gastroenterology-urology biopsy instrument Regulatory Class: Class II Product Code: KNW Dated: June 10, 2014 Received: June 11, 2014
Dear Ms. Greidanus:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
{1}------------------------------------------------
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
for
Sincerely yours,
# David Krause -S
- Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known) K141552
Device Name
Achieve Programmable Automatic Biopsy System
Indications for Use (Describe)
Intended for use in obtaining core biopsy samples from soft tissue such as kidney, liver, prostrate, spleen, lymph nodes, and various soft tissue masses. Not intended for use in bone.
The Achieve Programmable Automatic Biopsy System is also indicated to provide breast tissue samples for diagnostic sampling of breast abnormalities. It is designed to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality.
The extent of histologic abnormality cannot be reliably determined from its mammographic appearance. Therefore, the extent of removal of the imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality (e.g., malignancy). When the sampled abnormality is not histologically benign, it is essue margins be examined for completeness of removal using standard surgical procedures.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON A SEPARATE PAGE IF NEEDED.
### FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to
> Department of Health and Human Services Food and Drug Admınıstration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of ınformation unless it displays a currently valıd OMB number "
{3}------------------------------------------------
# 510(k) SUMMARY K141552
| SUBMITTER INFORMATION | |
|------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Name | CareFusion |
| Address | 75 North Fairway Drive, Vernon Hills, IL 60061 USA |
| Phone number | (847) 362-8103 |
| Fax number | (312) 949-0583 |
| Establishment Registration<br>Number | 1423507 |
| Name of contact person | Joy Greidanus |
| Date prepared | August 26, 2014 |
| DESCRIPTION OF DEVICE | |
| Trade or proprietary name | Achieve Programmable Automatic Biopsy Systems |
| Common or usual name | Soft Tissue Biopsy Needle |
| Classification name | Instrument, Biopsy |
| Classification panel | Gastroenterology/Urology |
| Regulation | Class II per 21CFR §876.1075 |
| Product Code(s) | KNW |
| Legally marketed device(s)<br>to which equivalence is<br>claimed | K960064 CareFusion Achieve (Formerly Bauer Medical)<br>and K133948 Bard Monopty |
| Reason for 510(k)<br>submission | Updates to labeling and device modifications. |
| Device description | The Achieve® Programmable Automatic Biopsy Systems are used to remove,<br>by cutting, a specimen of tissue for microscopic evaluation. The organs in<br>which the device may be used include but are not limited to breast, kidney,<br>liver, prostate, spleen and lymph nodes plus various soft tissue masses. The<br>device provides precise control and quality sampling capability when working<br>with calcified or fibrous lesions. The lightweight system offers spring-loaded<br>action for fast, accurate penetration of dense tissue. |
| Intended use of the device | The Achieve Programmable Automatic Biopsy System is intended for use in<br>obtaining core biopsy samples from soft tissue such as kidney, liver, prostrate,<br>spleen, lymph nodes, and various soft tissue masses. Not intended for use in<br>bone.<br><br>The Achieve Programmable Automatic Biopsy System is also indicated to<br>provide breast tissue samples for diagnostic sampling of breast abnormalities.<br>It is designed to provide breast tissue for histologic examination with partial or<br>complete removal of the imaged abnormality. |
A summary of 510(k) safety and effectiveness information in accordance with 21 CFR 807.92.
{4}------------------------------------------------
SUMMARY OF THE TECHNOLOGICAL CHARACTERISTICS OF THE DEVICE COMPARED TO THE PREDICATE DEVICE
| Characteristic | New Device | Predicates |
|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Mode of Action | Single Puncture and Multiple Samples | Same as predicates: K960064 CareFusion<br>Achieve (Formerly Bauer Medical) and<br>K133948 Bard Monopty |
| Firing modes | Automatic and Delay | Same as predicate: K960064 CareFusion<br>Achieve |
| Anatomical Sites | Breast, kidney, liver, prostate, spleen,<br>lymph nodes and various soft tissue<br>masses | Same as predicate: K960064 CareFusion<br>Achieve (Formerly Bauer Medical) and<br>K133948 Bard Monopty |
| CONCLUSION OF DEVICE COMPARISON | | |
| The technological characteristics of the proposed devices are substantially equivalent to the predicate. | | |
| PERFORMANCE DATA | | |
| SUMMARY OF NON-CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL<br>EQUIVALENCE | | |
| Characteristic | Standard/Test/FDA Guidance | |
| Biocompatibility | AAMI/ANSI/ISO 10993-1:2009 Biological evaluation of Medical Devices Part 1: Evaluation<br>and Testing | |
| Residuals | AAMI/ANSI/ISO 10993-7:2008 Biological evaluation of Medical Devices Part 7: Ethylene<br>Oxide Sterilization Residuals | |
| Performance | BS EN ISO 9626:1995: Stainless Steel Needle Tubing for the Manufacture of Medical<br>Devices. | |
| Performance | ISO 11737-1,2:2006 Sterilization of Medical Devices - Microbiological Methods | |
| Performance | ISO 11135:2007 Medical Device, Validation and Routine Control of Ethylene Oxide<br>Sterilization | |
| Performance | ISO 11138:1 2006 Sterilization of Healthcare Products, Biological Indicators | |
| Performance | AAMI TIR28:2009 Product Adoption and Process Equivalency for Ethylene Oxide<br>Sterilization | |
| Performance | ANSI/AAMI/ISO 11607:2006 Packaging for Terminally Sterilized Medical Devices | |
| Performance | ASTM F899-95 Standard Specification for Stainless Steel Billet, Bar and Wire for Surgical<br>Instruments | |
| Performance | ASTM F1980-07 Accelerated Aging of Sterile Barrier Systems | |
| Performance | BS/EN/ISO 9626:1995 Stainless Steel Needle Tubing for the Manufacture of Medical<br>Devices | |
| Performance | Biopsy Sample Testing - Comparison of samples obtained by predicate and proposed<br>devices to prove equivalency. | |
| Performance | Weld Strength Testing - Verification of the proposed device stylet weld strength to ensure<br>safety and effectiveness. | |
| Performance | Firing Speed Testing - Comparison of the firing speeds of the predicate and proposed<br>devices to prove equivalency. | |
| Performance | Ultrasound Visibility Testing - Verification of the proposed device ultrasound visibility to<br>ensure safety and effectiveness. | |
{5}------------------------------------------------
# SUMMARY OF CLINICAL TESTS CONDUCTED FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE AND/OR OF CLINICAL INFORMATION
N/A – No clinical tests were conducted for this submission
## CONCLUSIONS DRAWN FROM NON-CLINICAL AND CLINICAL DATA
The results of the non-clinical tests show the CareFusion Achieve Programmable Automatic Biopsy Systems meet or exceed all performance requirements, and are substantially equivalent to the predicate devices.
